CDT Equity (CDT) Total Debt (2023 - 2024)
CDT Equity's (CDT) quarterly Total Debt came in at $1.7 million in Q3 2024, up 341.51% on a QoQ basis from $383000.0 in Q2 2024.
CDT Equity (CDT) Total Debt (2023 - 2024) Analysis & Trends
CDT Equity (CDT) has 2 years of Total Debt data on file, last reported at $1.7 million in Q3 2024.
- Quarterly Total Debt changed N/A year-over-year to $1.7 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.7 million (changed N/A YoY) and the FY2023 annual result came in at $385000.0, changed N/A from the prior year.
- Total Debt grew to $1.7 million in Q3 2024, from $383000.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $1.7 million in Q3 2024 to a low of $383000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 383,000.00 |
| Dec 31, 2023 | 385,000.00 |